Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN , June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023.

Medtronic Board appoints Greg Lewis as new Director

DUBLIN and SAN DIEGO , June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

UnitedHealth Group

Health care stocks to check out in the stock market today.

Top Health Care Stocks To Buy Today? 2 To Know

Intuitive Surgical

Stryker

The healthcare industry is facing pent-up demand for surgeries. Health insurers may struggle with some additional costs as a result.

Elective Surgeries Are On the Rise: 3 Stocks That Can Benefit From This Trend

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced a pilot collaboration agreement with Medtronic, a global leader in healthcare technology, to expand access to Allurion's AI-powered weight loss program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The partnership enables Allurion to offer the Allurion Balloon and accelerate utilization of the Allurion Iris Artificial Intelligence (AI) Pla.

Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered Weight Loss Program

Johnson & Johnson

The global AI-in-healthcare market is on track to top $100 billion later this decade. Companies that invest in the area now could reap the rewards down the road.

AI May Transform Healthcare: 2 Top Stocks to Buy Now

The company marked the 46th year of dividend increases, a trend unlikely to stop any time soon.

Top Dividend Stocks: Steady Medtronic Raises Dividend For 46th Straight Year

Over the last few decades, medical device company Medtronic has made long-term investors rich. Cannabis company Cresco Labs is working hard to reduce costs and turn a profit.

2 Promising Stocks That Are Screaming Buys in June

Medtronic is weighing its next steps after losing another round in a long-running patent dispute with med-tech competitor Teleflex Inc.

Medtronic weighs appeal after losing patent case regarding catheter technology

SkyQuest's ENT Devices market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections. SkyQuest's ENT Devices market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is produced and published concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections.

ENT Devices Market Size to Grow Higher by 2030

A recent trend in the U.S. healthcare system could strongly benefit the medical device segment. The health care system is now addressing pent-up demand for procedures that were postponed during the hotter periods of the pandemic.

Why Medical Device Stocks Like Medtronic Were So Healthy Today

Charles River Laboratories

One of the greatest changes in the American landscape going forward will be demographics. The Baby Boomers make up the largest generation in the country's history.

3 Long-term Healthcare Stocks to Add to Your Portfolio

MDT, a member of the S&P Dividend Aristocrats index, recently provided weak guidance which dampens its low-dividend cover even more. We still appreciate some of the other dividend sub-plots. We shed some insight into the technical and valuation developments.

Is Medtronic's Dividend In A Good Place?

Medtronic plc (NYSE:MDT ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 12, 2023 1:40 PM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Conference Call Participants Jamie Perse - Goldman Sachs Jamie Perse All right. Good morning, everyone.

Medtronic plc (MDT) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

DUBLIN , June 12, 2023 /PRNewswire/ -- Medtronic plc  (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's (ADA) 83rd Scientific Sessions in San Diego on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.

Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions

Amazon

Moderna

AI stocks don't necessarily have to be technology companies. Some e-commerce and healthcare companies are investing in AI -- this can benefit their businesses and investors over time.

3 Top AI Stocks to Buy Hand Over Fist

Lowe's

Medtronic and Lowe's have both increased their dividend payments for more than 40 consecutive years. Medtronic expects new product launches, and it is also seeing a recovery in the volume of procedures.

2 Dividend Growth Stocks That Just Raised Their Payouts Again

Medtronic has struggled to grow in recent times, but it's put a transformation plan into action. At the same time, it's focusing on one of its strengths: the use of artificial intelligence in its medical devices.

Could AI Boost Growth at Medtronic?

American Electric Power Company

Amgen

Bank of America

Blackrock Inc

ConocoPhillips

Cisco Systems

CVS Health

Goldman Sachs

Coca-Cola

Morgan Stanley

Pfizer

PNC Financial Services

Phillips 66

Sempra Energy

Target

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 20 stocks on my high yield watchlist for June 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory. An equally weighted portfolio of these stocks underperformed the Vanguard High Yield Dividend ETF by about 1.5% during the month of May.

High Yield Stock Watchlist: June 2023

Intel

Lemonade

The Nasdaq, propelled partially by optimism about artificial intelligence (AI), is already in a bull market, as the index had soared 25% so far this year. The S&P 500, which is on the verge of a bull market as well, has also benefitted from investor enthusiasm related to the technology.

3 Stocks to Buy for the Coming AI-Powered Bull Market

DUBLIN , June 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer.

Medtronic names Ken Washington new Chief Technology and Innovation Officer

Medtronic's revenue and profits rose in the fourth quarter. The company's market-topping payout has room to grow.

Should Income Investors Buy This Soon-to-Be Dividend King?

Now that Johnson & Johnson has spun off its slow-moving consumer health division, its pharmaceutical and medical technology segments are expected to drive growth at a faster pace than usual. Medtronic is purely a medical device company with a slate of new product launches that could drive dividend growth in the years to come.

3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June

Automatic Data Processing

Albemarle

Cincinnati Financial

Clorox

Essex Property Trust

Federal Realty Investment Trust

Hormel Foods

Realty Income Corp

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

Walgreens

Dividend aristocrats are struggling in 2023, with the ProShares S&P 500 Dividend Aristocrats ETF down 4.71% in May. Three strategies for identifying winning aristocrats include focusing on undervalued stocks, fastest expected growth, and a blend of the two. Despite recent underperformance, long-term investors can find value in dividend aristocrats, as they have historically outperformed the S&P 500 index.

My Best Dividend Aristocrats For June 2023

Although the company posted upbeat Q1 results last week, the stock has declined due to lower-than-expected guidance for fiscal 2024.

News for Medtronic Stock (MDT)